Cargando…

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catapano, Alberico Luigi, Pirillo, Angela, Norata, Giuseppe Danilo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590683/ https://www.ncbi.nlm.nih.gov/pubmed/28919772 http://dx.doi.org/10.2147/VHRM.S130338

Ejemplares similares

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

LOX-1, OxLDL, and Atherosclerosis
por: Pirillo, Angela, et al.
Publicado: (2013)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
por: Bonacina, Fabrizia, et al.
Publicado: (2021)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
por: Ceballos-Macías, José Juan, et al.
Publicado: (2019)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

High density lipoproteins and atherosclerosis: emerging aspects
por: Sala, Federica, et al.
Publicado: (2012)

PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction
por: Da Dalt, Lorenzo, et al.
Publicado: (2021)

Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases
por: Pirillo, Angela, et al.
Publicado: (2013)

Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
por: Pirillo, Angela, et al.
Publicado: (2015)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia
por: Curia, Maria Cristina, et al.
Publicado: (2022)

Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
por: Bonacina, Fabrizia, et al.
Publicado: (2013)

Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis
por: Baragetti, Andrea, et al.
Publicado: (2021)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population
por: Predazzi, Irene Marta, et al.
Publicado: (2012)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events
por: Magnoni, Marco, et al.
Publicado: (2022)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review
por: Alam, Loba, et al.
Publicado: (2020)

Molecular Mechanisms Responsible for the Antiinflammatory and Protective Effect of HDL on the Endothelium
por: Norata, Giuseppe D, et al.
Publicado: (2005)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_huj1dta0ibctq77rnmh1ig6rdo